Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

Biotechnology

Healthcare
$8.91 -1.39%

-$0.26 today

Market cap
$761.36M
Beta
1.60
P/E (TTM)
-9.1
EPS (TTM)
-$1.98
52W Low $4.12High $25.77

Volume 1.11M

Average 1.02M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$22.80M

FY 2025 · Annual

Investing Cash Flow

-$101.83M

FY 2025 · Annual

Financing Cash Flow

$30.35M

FY 2025 · Annual

-69.3% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73.96M)(108.5M)(135.35M)(72.7M)(38.63M)
Depreciation & Amortization2.13M3.75M6.22M8.12M8.36M
Deferred Income Tax17K0000
Stock-Based Compensation5.2M11.66M16.67M18.13M18.87M
Change in Working Capital6.29M(2.13M)72.47M91.4M(9.19M)
Accounts Receivables0(187)1.9M332K(7M)
Inventory0187000
Accounts Payables(706K)(744K)5.76M6.25M(13.71M)
Other Working Capital6.99M(1.39M)64.81M84.81M11.52M
Other Non-Cash Items960K2.76M(3.81M)(2.95M)(2.2M)
Operating Cash Flow(59.36M)(92.47M)(43.8M)42M(22.8M)
Capital Expenditures(9.73M)(12.91M)(19.04M)(3.99M)(4.7M)
Acquisitions (Net)79K109K62K00
Purchases of Investments0(384.42M)(103.15M)(230.36M)(376.68M)
Sales of Investments0178M210.93M189.9M279.54M
Other Investing Activities00000
Investing Cash Flow(9.65M)(219.22M)88.8M(44.45M)(101.83M)
Debt Repayment00000
Common Stock Issued237.75M20.06M27.49M944K30.35M
Common Stock Repurchased000(641K)0
Dividends Paid00000
Other Financing Activities(3.19M)411K098.59M0
Financing Cash Flow377.56M20.47M27.49M98.89M30.35M
Effect of Forex Changes00000
Net Change in Cash308.55M(291.22M)72.49M96.44M(94.28M)
Free Cash Flow(69.1M)(105.38M)(62.84M)38.01M(27.5M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$38.6M
+ D&A$8.4M
+ Stock-Based Comp$18.9M
+ Deferred Tax$0
- Working Capital-$9.2M
- Other Non-Cash-$2.2M
= Operating Cash Flow-$22.8M
- Capex-$4.7M
= Free Cash Flow-$27.5M

Analysis

FY2025 free cash flow is -$27.5M. FCF conversion is 71.2% of net income. Operating cash flow was -$22.8M, with capex of -$4.7M. The largest bridge item is Stock-Based Comp at $18.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
4Statement of changes in beneficial ownershipOct 6, 2026
8-KCurrent reportOct 1, 2026
8-KCurrent reportSep 8, 2026

Does GLUE generate free cash flow?

Monte Rosa Therapeutics, Inc. (GLUE) generated -$27.50M of free cash flow in fiscal 2025.

How much operating cash flow does GLUE produce?

Operating cash flow was -$22.80M, before capital expenditures of $4.70M.